NASDAQ: SPPI INVESTOR ALERT: Berger Montague Advises Spectrum Pharmaceuticals (NASDAQ: SPPI) Investors of September 24, 2025 Deadline
NASDAQ: SPPI INVESTOR ALERT: Berger Montague Advises Spectrum Pharmaceuticals (NASDAQ: SPPI) Investors of September 24, 2025 Deadline |
| [13-August-2025] |
PHILADELPHIA, Aug. 13, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC is investigating securities fraud claims against Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) ("Spectrum" or the "Company") on behalf of investors who purchased or otherwise acquired common shares of Spectrum between March 17, 2022 through September 22, 2022 (the "Class Period").
Investor Deadline: Investors who purchased or acquired Spectrum securities during the Class Period may, no later than September 24, 2025, seek to be appointed as a lead plaintiff representative of the class. To learn your rights, CLICK HERE. Spectrum is a biopharmaceutical company focused on oncology treatments. The class action lawsuit alleges that Spectrum made false or misleading statements to investors regarding its Pinnacle Study, a clinical trial involving poziotinib, a drug intended to treat certain lung cancer patients. Spectrum shares were delisted following the Company's merger with Assertio Holdings, Inc. (NASDAQ: ASRT). If you are a Spectrum investor and would like to learn more about this action, CLICK HERE or please contact Berger Montague: Andrew Abramowitz at aabramowitz@bergermontague.com or (215) 875-3015, or Caitlin Adorni at cadorni@bergermontague.com or (267)764-4865. About Berger Montague For more information or to discuss your rights, please contact: Caitlin Adorni
SOURCE Berger Montague | ||
Company Codes: NASDAQ:SPPI,NASDAQ-CM:ASRT |
View original content to download multimedia:
